Glial Cell Therapy Gets FDA's Orphan Drug Designation for Transverse Myelitis

The Company has obtained Investigational New Drug clearance for Phase 1/2a trials of Q-Cells in both TM and amyotrophic lateral sclerosis.

Source link

Related posts

Myasthenic congenital myopathy from recessive mutations at a single residue in NaV1.4


A novel method for quantifying axon degeneration.


18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy